Amryt Pharma (Amryt Pharma) Debt-to-EBITDA : 10.17 (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amryt Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $1.0 Mil. Amryt Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $211.8 Mil. Amryt Pharma's annualized EBITDA for the quarter that ended in Sep. 2022 was $20.9 Mil. Amryt Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was 10.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Amryt Pharma's Debt-to-EBITDA or its related term are showing as below:

AMYT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.82 Med: -0.67 Max: 2.95
Current: 2.41

During the past 12 years, the highest Debt-to-EBITDA Ratio of Amryt Pharma was 2.95. The lowest was -4.82. And the median was -0.67.

AMYT's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.7 vs AMYT: 2.41

Amryt Pharma Debt-to-EBITDA Historical Data

The historical data trend for Amryt Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Debt-to-EBITDA Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.42

-0.67

-4.22

-4.82

2.95

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-EBITDA	Get a 7-Day Free Trial															-3.84	0.74	55.20	3.70	10.17

Competitive Comparison of Amryt Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Debt-to-EBITDA falls into.

Amryt Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amryt Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	199.183)	/	67.642
	=	2.94

Amryt Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.966	+	211.825)	/	20.932
	=	10.17

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.

Amryt Pharma (NAS:AMYT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Amryt Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).